FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
NEWTON, Mass., Feb. 03, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming Leerink Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:30 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm’s SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
